Stock OGEN ORAGENICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Oragenics, Inc.

Equities

OGEN

US6840235005

Market Closed - Nyse
Other stock markets
 16:00:00 2024-05-20 EDT 		5-day change 1st Jan Change
3.07 USD +31.76% Intraday chart for Oragenics, Inc. +104.67% -45.43%
05-16 Sector Update: Health Care Stocks Ease Thursday Afternoon MT
05-16 Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
AQ
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
AQ
Sector Update: Health Care Stocks Ease Thursday Afternoon
MT
Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise
MT
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
AQ
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
CI
Oragenics: Q1 Earnings Snapshot
AQ
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
AQ
Oragenics, Inc. Announces Partnership with Avance Clinical to Conduct Phase II Clinical Trial in Australia
CI
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
BU
North American Morning Briefing : Big Banks Kick -2-
DJ
Oragenics, Inc. Files 10K and Provides Company Update
BU
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
BU
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
BU
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
CI
Oragenics Announces Closing of Public Offering
AQ
Oragenics Announces Closing of Public Offering
BU
Top Midday Decliners
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OGEN Stock
  4. News Oragenics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW